These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

468 related articles for article (PubMed ID: 11828862)

  • 1. Antiretroviral therapy for HIV: drug resistance and sequencing.
    Burkle WS
    J Assoc Nurses AIDS Care; 2002; 13(1):76-80. PubMed ID: 11828862
    [No Abstract]   [Full Text] [Related]  

  • 2. HIV therapeutics: points from the recent literature.
    Laurence J
    AIDS Read; 2003 Jul; 13(7):305, 307. PubMed ID: 12889448
    [No Abstract]   [Full Text] [Related]  

  • 3. Preventing and managing antiretroviral drug resistance.
    Kuritzkes DR
    AIDS Patient Care STDS; 2004 May; 18(5):259-73. PubMed ID: 15186710
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antiretroviral therapy in HIV-infected infants and children.
    Marón G; Gaur AH; Flynn PM
    Pediatr Infect Dis J; 2010 Apr; 29(4):360-3. PubMed ID: 20351530
    [No Abstract]   [Full Text] [Related]  

  • 5. Antiretroviral resistance.
    Geretti AM
    J HIV Ther; 2006 Dec; 11(4):72-3. PubMed ID: 17578209
    [No Abstract]   [Full Text] [Related]  

  • 6. HIV-1 group O resistance pathway with raltegravir is similar to HIV-1 group M.
    Alessandri-Gradt E; Morgand M; Delaugerre C; Peytavin G; Sellier P; Simon F; Plantier JC
    AIDS; 2015 Jun; 29(10):1271-3. PubMed ID: 26035328
    [No Abstract]   [Full Text] [Related]  

  • 7. Optimal antiretroviral therapy: HIV-1 treatment strategies to avoid and overcome drug resistance.
    Grant PM; Zolopa AR
    Curr Opin Investig Drugs; 2010 Aug; 11(8):901-10. PubMed ID: 20721832
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dolutegravir: successful experience in a challenging patient.
    Bonadies G; Maraolo AE; Tambaro O; Palmiero G; Di Filippo G; Orlando R
    AIDS; 2015 Jun; 29(10):1269-71. PubMed ID: 26035327
    [No Abstract]   [Full Text] [Related]  

  • 9. Predicting antiretroviral drug resistance from the latest or the cumulative genotype.
    Garcia F; Alvarez M; Fox Z; Garcia-Diaz A; Guillot V; Johnson M; Chueca N; Phillips A; Hernández-Quero J; Geretti AM
    Antivir Ther; 2011; 16(3):373-82. PubMed ID: 21555820
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiretroviral update: recent advances expand options for patients with HIV.
    Santhanam H; Goins M
    Adv Nurse Pract; 2004 Nov; 12(11):53-4, 56. PubMed ID: 15559568
    [No Abstract]   [Full Text] [Related]  

  • 12. Basis of selection of first and second line highly active antiretroviral therapy for HIV/AIDS on genetic barrier to resistance: a literature review.
    Katusiime C; Ocama P; Kambugu A
    Afr Health Sci; 2014 Sep; 14(3):679-81. PubMed ID: 25352888
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HIV news from Buenos Aires: Part 1--the Zahir and the band-aid. 1st IAS conference on HIV pathogenesis and treatment. July 8-11, 2001, Buenos Aires.
    Mascolini M
    IAPAC Mon; 2001 Sep; 7(9):274-89. PubMed ID: 11708272
    [No Abstract]   [Full Text] [Related]  

  • 14. HIV-1 drug resistance testing. IAPAC sessions 2001, July 18-19, 2001 - Chicago.
    Simon VA;
    IAPAC Mon; 2001 Aug; 7(8):235-7. PubMed ID: 11708276
    [No Abstract]   [Full Text] [Related]  

  • 15. Therapies. Confronting the limits of success.
    Cohen J
    Science; 2002 Jun; 296(5577):2320-4. PubMed ID: 12089422
    [No Abstract]   [Full Text] [Related]  

  • 16. Persistence of HIV-1 drug resistance mutations and emergence during antiretroviral treatment interruption: considerations from a clinical case.
    Torti C; Moretti F; Uccelli MC; Tirelli V; Quiros-Roldan E; Gargiulo F; Carosi G
    Med Sci Monit; 2003 Apr; 9(4):CS16-9. PubMed ID: 12709675
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Building a better nucleoside/nucleotide analogue backbone: pharmacokinetic and resistance considerations.
    Zolopa AR
    AIDS Read; 2003 Sep; ():S9-15. PubMed ID: 14601554
    [No Abstract]   [Full Text] [Related]  

  • 18. Treatment of antiretroviral-drug-resistant HIV-1 infection.
    Deeks SG
    Lancet; 2003 Dec; 362(9400):2002-11. PubMed ID: 14683662
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of HIV infection after triple class failure.
    Cossarini F; Spagnuolo V; Gianotti N; Carbone A; Lazzarin A; Castagna A
    New Microbiol; 2013 Jan; 36(1):23-39. PubMed ID: 23435813
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [A problem of the HIV drug resistance].
    Nosik MN
    Vopr Virusol; 2014; 59(4):5-9. PubMed ID: 25549461
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.